Communiqués COMPASS Pathways plc

Actions

CMPS

US20451W1018

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/09/2026			Varia. 5j.	Varia. 1 janv.
13,23 ^USD	-0,08%		-9,45%	+91,74%

06/08	COMPASS Pathways plc : RBC Capital Markets reste à l'achat	ZM
06/08	COMPASS Pathways plc : B. Riley persiste à l'achat	ZM

Communiqués

12:30	Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree	BU
01/09	Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026	BU
06/08	Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026	BU
06/08	Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin	BU
05/08	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/08	Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights	BU
29/07	Compass Pathways publiera le 5 août 2026 ses résultats financiers du deuxième trimestre et du premier semestre 2026	BU
29/07	Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026	BU
21/07	A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening	AQ
16/07	Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy	BU
07/07	Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile	BU
02/07	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
26/06	A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year	AQ
08/06	Compass Pathways Announces New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
05/06	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
02/06	FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate	AQ
28/05	COMPASS Pathways : 2026 AGM Voting Results	PU
28/05	Compass Pathways Elects Kathleen Tregoning to Board of Directors	BU
26/05	Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026	BU
14/05	Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026	BU
13/05	COMPASS Pathways : Leading the Transformation of Mental Health Care	PU
13/05	Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights	BU
06/05	Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026	BU
06/05	Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
27/04	Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher	AQ